Back to the main directory
EarningsReview / Equity
- VietNam Holding - Investing for the long term by Edison Investment Research
- What is management saying? by BNP Paribas Exane
- Are we blown away? Not yet by BNP Paribas Exane
- Flat Glass Group (6865 HK/601865 CH) by HSBC
- Cambi (Hold, TP: NOK9.00) - Time for a pause by DnB Markets
- Komplett (Hold, TP: NOK17.00) - Gross margins turning by DnB Markets
- Hexpol (Hold, TP: SEK130.00) - Undramatic quarter by DnB Markets
- Epiroc (Hold, TP: SEK210.00) - Continued strong momentum by DnB Markets
- Itaú BBA on ClearSale: Skies Clearing in the Wake of the Perfect Storm; Journey to Positive FCF Continues by Itau
- The next AT1 on your radar by BNP Paribas Exane
- Workers of the world, sorry! by BNP Paribas Exane
- Investment Daily 28/03/2023 by BNP Paribas Exane
- TAKE OFF - Résilience by MidCap Partners
- Doxee - Le MiSE, par l'intermédiaire du Fonds de croissance durable, financera la R&D de Doxee avec €2.9m by MidCap Partners
- Actia Group - Sur la bonne trajectoire ! by MidCap Partners
- TAKE OFF - Resilience by MidCap Partners
- Doxee - MiSE, Through the Sustainable Growth Fund, Will Finance Doxee’s R&D With €2.9m by MidCap Partners
- Virbac - ANIMAL HEALTH: Update on Virbac & Vetoquinol by MidCap Partners
- Prodways - Record FY 2022 by MidCap Partners
- INVEST SECURITIES - DIASORIN : Visibilité encore faible à moyen terme - NEUTRE, OC 104€ (vs 127€) by Invest Securities
- INVEST SECURITIES - TME PHARMA : Médiane de survie supérieure à 12 mois… rdv à 15 mois - ACHAT, OC 4,2€ by Invest Securities
- Midatech Pharma - Development pipeline expands with MTD217 by Edison Investment Research
- EQUITA SIM: DIASORIN (BUY; Unchanged) - 4Q22 results by Equita Sim
- Fuling Zhacai (002507 CH) by HSBC
- AFT Pharmaceuticals - Maxigesic international momentum continues by Edison Investment Research